Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1999-11-4
pubmed:abstractText
The antimicrobial activities of trovafloxacin, moxifloxacin, sanfetrinem, quinupristin-dalfopristin, and 14 other antimicrobial agents against 218 Bacteroides fragilis group strains were determined. A group of 10 imipenem-resistant strains were also tested. Imipenem, meropenem, and sanfetrinem had the lowest MICs of all of the beta-lactams. Quinupristin-dalfopristin inhibited all of the strains at 2 microg/ml. Overall, the MICs of trovafloxacin and moxifloxacin for 90% of the strains tested were 1 and 2 microg/ml, respectively.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-10381111, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-1295754, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-1396757, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-2559846, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-7840557, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-7924220, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-8226424, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-8324152, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-8878617, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-8953108, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-9056020, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-9372419, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-9420050, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-9517922, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-9593145, http://linkedlifedata.com/resource/pubmed/commentcorrection/10471590-9665302
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aza Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Fluoroquinolones, http://linkedlifedata.com/resource/pubmed/chemical/Lactams, http://linkedlifedata.com/resource/pubmed/chemical/Naphthyridines, http://linkedlifedata.com/resource/pubmed/chemical/Quinolines, http://linkedlifedata.com/resource/pubmed/chemical/Virginiamycin, http://linkedlifedata.com/resource/pubmed/chemical/moxifloxacin, http://linkedlifedata.com/resource/pubmed/chemical/quinupristin-dalfopristin, http://linkedlifedata.com/resource/pubmed/chemical/sanfetrinem, http://linkedlifedata.com/resource/pubmed/chemical/trovafloxacin
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2320-2
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
pubmed:affiliation
Servicio de Microbiología Clínica, Hospital Clínico San Carlos, 28040 Madrid, Spain. cbetriu@efd.net
pubmed:publicationType
Journal Article, Comparative Study